HYUNDAI FEED Inc (016790) - Total Liabilities

Latest as of June 2025: ₩28.17 Billion KRW ≈ $19.09 Million USD

Based on the latest financial reports, HYUNDAI FEED Inc (016790) has total liabilities worth ₩28.17 Billion KRW (≈ $19.09 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore HYUNDAI FEED Inc (016790) equity growth momentum to track the company's year-over-year net asset growth rate.

HYUNDAI FEED Inc - Total Liabilities Trend (2015–2024)

This chart illustrates how HYUNDAI FEED Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of HYUNDAI FEED Inc to measure how efficiently the company converts operating cash flow to free cash.

HYUNDAI FEED Inc Competitors by Total Liabilities

The table below lists competitors of HYUNDAI FEED Inc ranked by their total liabilities.

Company Country Total Liabilities
Energy World Corporation Ltd
AU:EWC
Australia AU$480.12 Million
DMS Co.Ltd
KQ:068790
Korea ₩135.93 Billion
Dong Hai JSC of Bentre
VN:DHC
Vietnam ₫1.37 Trillion
FACT II Acquisition Corp. Class A Ordinary Shares
NASDAQ:FACT
USA $9.52 Million
John Hancock Income Securities Closed Fund
NYSE:JHS
USA $93.79 Million
Land General Bhd
KLSE:3174
Malaysia RM644.36 Million
Cannara Biotech Inc
V:LOVE
Canada CA$62.63 Million
ENIGMATIG LIMITED
NYSE MKT:EGG
USA $1.73 Million

Liability Composition Analysis (2015–2024)

This chart breaks down HYUNDAI FEED Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HYUNDAI FEED Inc (016790) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HYUNDAI FEED Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HYUNDAI FEED Inc (2015–2024)

The table below shows the annual total liabilities of HYUNDAI FEED Inc from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩28.05 Billion
≈ $19.01 Million
-84.47%
2023-12-31 ₩180.58 Billion
≈ $122.38 Million
-21.11%
2022-12-31 ₩228.90 Billion
≈ $155.12 Million
+533.27%
2021-12-31 ₩36.15 Billion
≈ $24.50 Million
-7.88%
2020-12-31 ₩39.24 Billion
≈ $26.59 Million
+3.47%
2019-12-31 ₩37.92 Billion
≈ $25.70 Million
+1.87%
2018-12-31 ₩37.23 Billion
≈ $25.23 Million
+3.12%
2017-12-31 ₩36.10 Billion
≈ $24.46 Million
-5.78%
2016-12-31 ₩38.31 Billion
≈ $25.97 Million
-41.07%
2015-12-31 ₩65.02 Billion
≈ $44.06 Million
--

About HYUNDAI FEED Inc

KQ:016790 Korea Packaged Foods
Market Cap
$126.96 Million
₩187.34 Billion KRW
Market Cap Rank
#18246 Global
#769 in Korea
Share Price
₩994.00
Change (1 day)
+0.00%
52-Week Range
₩994.00 - ₩994.00
All Time High
₩15077.70
About

HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is invo… Read more